A combination of Oncolytics Biotech’s investigational therapy Reolysin (pelareorep) with anti-cancer medication Opdivo (nivolumab) and standard of care will be tested in…
Myeloma
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Latest news
The U.S. Food and Drug Administration has approved a combination of once-weekly Kyprolis (carfilzomib), developed by Amgen, and dexamethasone for the treatment of multiple…
Molecular Templates has partnered with Takeda to develop engineered toxin bodies (EBTs) — a next-generation immuno-oncology therapy that delivers toxic payloads to cancer cells — targeting the…
The European Medicines Agency has validated Bristol-Myers Squibb’s application for Empliciti (elotuzumab), in combination with Pomalyst (pomalidomide) and low-dose dexamethasone, for the treatment of…
Updated results from a Phase 2b clinical trial continue to support Karyopharm Therapeutics‘ investigative oral therapy selinexor (KPT-330) as a promising approach for heavily-treated multiple myeloma…
In an effort to inform multiple myeloma patients and their loved ones about cutting-edge research and what it means for them, Patient Power…
